Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer PURPOSE: Reverse transcription-polymerase chain reaction ...

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer. Methods: This was a retrospective study of 116 patients with ductal invasive breast ...

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step ...

Polymerase chain reaction (PCR) tests have become routine because of the COVID-19 pandemic, with more than a million PCR tests being carried out daily in the United States alone. What are now commonly ...